Company news

Arbutus Biopharma Corporation news in 2023

Arbutus Biopharma Corporation's news releases, calls and decks from 2023, newest first.

View company

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

November 8, 2023

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 6, 2023

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

November 6, 2023

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

October 23, 2023

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

October 17, 2023

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

October 10, 2023

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

September 10, 2023

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

August 2, 2023

Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update

July 19, 2023

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

July 11, 2023

Arbutus Appoints Two New Executives

July 9, 2023

Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023

June 20, 2023

Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody

June 20, 2023

Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023

June 6, 2023

Arbutus to Present at Jefferies Healthcare Conference

May 30, 2023

Arbutus to Present at JMP Securities Life Sciences Conference

May 8, 2023

Arbutus Reports First Quarter 2023 Financial Results and Corporate Update

May 3, 2023

Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023

April 26, 2023

Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor

April 24, 2023

Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update

April 19, 2023

Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023

April 17, 2023

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech

April 3, 2023

Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161

March 15, 2023

Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research

March 13, 2023

Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update

March 1, 2023

Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update

February 15, 2023

Arbutus to Participate in Three Upcoming Investor Conferences

February 5, 2023

Arbutus Announces Resignation of Board Member

January 26, 2023

Arbutus Announces 2023 Corporate Objectives and Provides Financial Update

January 4, 2023

Calls in 2023

Decks in 2023